Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas.
about
APRIL mediates peritoneal B-1 cell homeostasis.Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.TACI expression and signaling in chronic lymphocytic leukemiaMalignancies in systemic lupus erythematosus: a 2015 update.The design and characterization of receptor-selective APRIL variantsClinical targeting of the TNF and TNFR superfamiliesAPRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?Clinical significance of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Modeling the chronic lymphocytic leukemia microenvironment in vitro.Expression of B-cell activating factor, a proliferating inducing ligand and its receptors in primary central nervous system lymphoma.Neutrophils trigger a NF-κB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas.Circulating APRIL levels are correlated with advanced disease and prognosis in rectal cancer patientsMacrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling.B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
P2860
Q33758475-9C94D410-6DA7-4B70-AFD0-7E699871DFBFQ34008992-428A5690-4B84-4E44-8B68-96D0F028CF66Q35534809-BB34B20D-D362-4927-BEBD-CFF43521652DQ36035448-700ACB19-ED09-475C-8AE6-58458E57091AQ36347872-3D25644A-B15D-45B5-A461-F6CA39493CB4Q36762882-4DC6E6EB-B2D3-489A-B2FA-9121BB76A071Q37035836-6896798F-6A31-42F7-A633-D4BFD7FAB240Q38365867-DF577F28-9D66-452E-9AF3-B0C041BB59E3Q38941414-C061030C-EC47-400D-A058-0087C276C3A8Q38984569-EBAA2857-55B5-4A50-B403-FACA3843CFB5Q40957585-2ACE1006-2694-4B0B-9B1D-E5DBCB936309Q41061029-F4EB7FDA-8C2B-43D2-B9FE-2E1A585A5501Q41082092-52762A0E-8763-4D3F-9E5D-51E73D36EFB5Q42367941-C4D9FFC8-1212-476C-86B8-0A1E83EB144DQ45833017-50E54538-F221-494F-8264-4411AB421FC8Q49539698-41B727D2-F059-4294-B315-C8A264E90AC0Q58790069-B7690C93-3D10-47A3-994E-4A8922DD5F54
P2860
Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Development and characterizati ...... treatment of B-cell lymphomas.
@en
Development and characterizati ...... treatment of B-cell lymphomas.
@nl
type
label
Development and characterizati ...... treatment of B-cell lymphomas.
@en
Development and characterizati ...... treatment of B-cell lymphomas.
@nl
prefLabel
Development and characterizati ...... treatment of B-cell lymphomas.
@en
Development and characterizati ...... treatment of B-cell lymphomas.
@nl
P2093
P1433
P1476
Development and characterizati ...... treatment of B-cell lymphomas.
@en
P2093
Arnon P Kater
Eric Eldering
Fiona C Kimberley
Hans Rodermond
Hans van Eenennaam
Jan Paul Medema
Katherine Cameron
Marco Guadagnoli
Paul M Vink
P304
P356
10.1182/BLOOD-2011-01-330852
P407
P577
2011-05-04T00:00:00Z